img

Global Neuroprotective Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuroprotective Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
The global Neuroprotective Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Neuroprotective Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Neuroprotective Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Neuroprotective Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Neuroprotective Drugs include Genervon, NeuroVive Pharmaceutical, Ceregene, BHR Pharma, Neuren Pharmaceuticals, Allon therapeutics and Bionure, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Neuroprotective Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Neuroprotective Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Neuroprotective Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Neuroprotective Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Genervon
NeuroVive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon therapeutics
Bionure
By Type
Cholinesterase inhibitors
Anti-inflammatory
Others
By Application
Alzheimer's disease
Parkinson's disease
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Neuroprotective Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroprotective Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Neuroprotective Drugs Definition
1.2 Market by Type
1.2.1 Global Neuroprotective Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Cholinesterase inhibitors
1.2.3 Anti-inflammatory
1.2.4 Others
1.3 Market Segment by Application
1.3.1 Global Neuroprotective Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Alzheimer's disease
1.3.3 Parkinson's disease
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Neuroprotective Drugs Sales
2.1 Global Neuroprotective Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Neuroprotective Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Neuroprotective Drugs Revenue by Region
2.3.1 Global Neuroprotective Drugs Revenue by Region (2018-2024)
2.3.2 Global Neuroprotective Drugs Revenue by Region (2024-2034)
2.4 Global Neuroprotective Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Neuroprotective Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Neuroprotective Drugs Sales Quantity by Region
2.6.1 Global Neuroprotective Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Neuroprotective Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Neuroprotective Drugs Sales Quantity by Manufacturers
3.1.1 Global Neuroprotective Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Neuroprotective Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Neuroprotective Drugs Sales in 2022
3.2 Global Neuroprotective Drugs Revenue by Manufacturers
3.2.1 Global Neuroprotective Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Neuroprotective Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neuroprotective Drugs Revenue in 2022
3.3 Global Neuroprotective Drugs Sales Price by Manufacturers
3.4 Global Key Players of Neuroprotective Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neuroprotective Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neuroprotective Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Neuroprotective Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Neuroprotective Drugs Sales Quantity by Type
4.1.1 Global Neuroprotective Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Neuroprotective Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Neuroprotective Drugs Revenue by Type
4.2.1 Global Neuroprotective Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Neuroprotective Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Neuroprotective Drugs Price by Type
4.3.1 Global Neuroprotective Drugs Price by Type (2018-2024)
4.3.2 Global Neuroprotective Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Neuroprotective Drugs Sales Quantity by Application
5.1.1 Global Neuroprotective Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Neuroprotective Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Neuroprotective Drugs Revenue by Application
5.2.1 Global Neuroprotective Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Neuroprotective Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Neuroprotective Drugs Price by Application
5.3.1 Global Neuroprotective Drugs Price by Application (2018-2024)
5.3.2 Global Neuroprotective Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Neuroprotective Drugs Sales by Company
6.1.1 North America Neuroprotective Drugs Revenue by Company (2018-2024)
6.1.2 North America Neuroprotective Drugs Sales Quantity by Company (2018-2024)
6.2 North America Neuroprotective Drugs Market Size by Type
6.2.1 North America Neuroprotective Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Neuroprotective Drugs Revenue by Type (2018-2034)
6.3 North America Neuroprotective Drugs Market Size by Application
6.3.1 North America Neuroprotective Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Neuroprotective Drugs Revenue by Application (2018-2034)
6.4 North America Neuroprotective Drugs Market Size by Country
6.4.1 North America Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Neuroprotective Drugs Revenue by Country (2018-2034)
6.4.3 North America Neuroprotective Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neuroprotective Drugs Sales by Company
7.1.1 Europe Neuroprotective Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Neuroprotective Drugs Revenue by Company (2018-2024)
7.2 Europe Neuroprotective Drugs Market Size by Type
7.2.1 Europe Neuroprotective Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Neuroprotective Drugs Revenue by Type (2018-2034)
7.3 Europe Neuroprotective Drugs Market Size by Application
7.3.1 Europe Neuroprotective Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Neuroprotective Drugs Revenue by Application (2018-2034)
7.4 Europe Neuroprotective Drugs Market Size by Country
7.4.1 Europe Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Neuroprotective Drugs Revenue by Country (2018-2034)
7.4.3 Europe Neuroprotective Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Neuroprotective Drugs Sales by Company
8.1.1 China Neuroprotective Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Neuroprotective Drugs Revenue by Company (2018-2024)
8.2 China Neuroprotective Drugs Market Size by Type
8.2.1 China Neuroprotective Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Neuroprotective Drugs Revenue by Type (2018-2034)
8.3 China Neuroprotective Drugs Market Size by Application
8.3.1 China Neuroprotective Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Neuroprotective Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Neuroprotective Drugs Sales by Company
9.1.1 APAC Neuroprotective Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Neuroprotective Drugs Revenue by Company (2018-2024)
9.2 APAC Neuroprotective Drugs Market Size by Type
9.2.1 APAC Neuroprotective Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Neuroprotective Drugs Revenue by Type (2018-2034)
9.3 APAC Neuroprotective Drugs Market Size by Application
9.3.1 APAC Neuroprotective Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Neuroprotective Drugs Revenue by Application (2018-2034)
9.4 APAC Neuroprotective Drugs Market Size by Region
9.4.1 APAC Neuroprotective Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Neuroprotective Drugs Revenue by Region (2018-2034)
9.4.3 APAC Neuroprotective Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neuroprotective Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Neuroprotective Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Neuroprotective Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Neuroprotective Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Genervon
11.1.1 Genervon Company Information
11.1.2 Genervon Overview
11.1.3 Genervon Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Genervon Neuroprotective Drugs Products and Services
11.1.5 Genervon Neuroprotective Drugs SWOT Analysis
11.1.6 Genervon Recent Developments
11.2 NeuroVive Pharmaceutical
11.2.1 NeuroVive Pharmaceutical Company Information
11.2.2 NeuroVive Pharmaceutical Overview
11.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 NeuroVive Pharmaceutical Neuroprotective Drugs Products and Services
11.2.5 NeuroVive Pharmaceutical Neuroprotective Drugs SWOT Analysis
11.2.6 NeuroVive Pharmaceutical Recent Developments
11.3 Ceregene
11.3.1 Ceregene Company Information
11.3.2 Ceregene Overview
11.3.3 Ceregene Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Ceregene Neuroprotective Drugs Products and Services
11.3.5 Ceregene Neuroprotective Drugs SWOT Analysis
11.3.6 Ceregene Recent Developments
11.4 BHR Pharma
11.4.1 BHR Pharma Company Information
11.4.2 BHR Pharma Overview
11.4.3 BHR Pharma Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 BHR Pharma Neuroprotective Drugs Products and Services
11.4.5 BHR Pharma Neuroprotective Drugs SWOT Analysis
11.4.6 BHR Pharma Recent Developments
11.5 Neuren Pharmaceuticals
11.5.1 Neuren Pharmaceuticals Company Information
11.5.2 Neuren Pharmaceuticals Overview
11.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Neuren Pharmaceuticals Neuroprotective Drugs Products and Services
11.5.5 Neuren Pharmaceuticals Neuroprotective Drugs SWOT Analysis
11.5.6 Neuren Pharmaceuticals Recent Developments
11.6 Allon therapeutics
11.6.1 Allon therapeutics Company Information
11.6.2 Allon therapeutics Overview
11.6.3 Allon therapeutics Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Allon therapeutics Neuroprotective Drugs Products and Services
11.6.5 Allon therapeutics Neuroprotective Drugs SWOT Analysis
11.6.6 Allon therapeutics Recent Developments
11.7 Bionure
11.7.1 Bionure Company Information
11.7.2 Bionure Overview
11.7.3 Bionure Neuroprotective Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Bionure Neuroprotective Drugs Products and Services
11.7.5 Bionure Neuroprotective Drugs SWOT Analysis
11.7.6 Bionure Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Neuroprotective Drugs Value Chain Analysis
12.2 Neuroprotective Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neuroprotective Drugs Production Mode & Process
12.4 Neuroprotective Drugs Sales and Marketing
12.4.1 Neuroprotective Drugs Sales Channels
12.4.2 Neuroprotective Drugs Distributors
12.5 Neuroprotective Drugs Customers
13 Market Dynamics
13.1 Neuroprotective Drugs Industry Trends
13.2 Neuroprotective Drugs Market Drivers
13.3 Neuroprotective Drugs Market Challenges
13.4 Neuroprotective Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neuroprotective Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Cholinesterase inhibitors
Table 3. Major Manufacturers of Anti-inflammatory
Table 4. Major Manufacturers of Others
Table 5. Global Neuroprotective Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Neuroprotective Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Neuroprotective Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Neuroprotective Drugs Revenue Market Share by Region (2018-2024)
Table 9. Global Neuroprotective Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Neuroprotective Drugs Revenue Market Share by Region (2024-2034)
Table 11. Global Neuroprotective Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (MT)
Table 12. Global Neuroprotective Drugs Sales by Region (2018-2024) & (MT)
Table 13. Global Neuroprotective Drugs Sales Market Share by Region (2018-2024)
Table 14. Global Neuroprotective Drugs Sales by Region (2024-2034) & (MT)
Table 15. Global Neuroprotective Drugs Sales Market Share by Region (2024-2034)
Table 16. Global Neuroprotective Drugs Sales Quantity by Manufacturers (2018-2024) & (MT)
Table 17. Global Neuroprotective Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Neuroprotective Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Neuroprotective Drugs Revenue Share by Manufacturers (2018-2024)
Table 20. Global Neuroprotective Drugs Price by Manufacturers 2018-2024 (USD/Kg)
Table 21. Global Key Players of Neuroprotective Drugs, Industry Ranking, 2021 VS 2022
Table 22. Global Neuroprotective Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Neuroprotective Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroprotective Drugs as of 2022)
Table 24. Global Key Manufacturers of Neuroprotective Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Neuroprotective Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Neuroprotective Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 29. Global Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 30. Global Neuroprotective Drugs Sales Quantity Share by Type (2018-2024)
Table 31. Global Neuroprotective Drugs Sales Quantity Share by Type (2024-2034)
Table 32. Global Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Neuroprotective Drugs Revenue Share by Type (2018-2024)
Table 35. Global Neuroprotective Drugs Revenue Share by Type (2024-2034)
Table 36. Neuroprotective Drugs Price by Type (2018-2024) & (USD/Kg)
Table 37. Global Neuroprotective Drugs Price Forecast by Type (2024-2034) & (USD/Kg)
Table 38. Global Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 39. Global Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 40. Global Neuroprotective Drugs Sales Quantity Share by Application (2018-2024)
Table 41. Global Neuroprotective Drugs Sales Quantity Share by Application (2024-2034)
Table 42. Global Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Neuroprotective Drugs Revenue Share by Application (2018-2024)
Table 45. Global Neuroprotective Drugs Revenue Share by Application (2024-2034)
Table 46. Neuroprotective Drugs Price by Application (2018-2024) & (USD/Kg)
Table 47. Global Neuroprotective Drugs Price Forecast by Application (2024-2034) & (USD/Kg)
Table 48. North America Neuroprotective Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Neuroprotective Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 50. North America Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 51. North America Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 52. North America Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 55. North America Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 56. North America Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Neuroprotective Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Neuroprotective Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Neuroprotective Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 62. North America Neuroprotective Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 63. Europe Neuroprotective Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 64. Europe Neuroprotective Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 66. Europe Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 67. Europe Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 70. Europe Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 71. Europe Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Neuroprotective Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Neuroprotective Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Neuroprotective Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 77. Europe Neuroprotective Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 78. China Neuroprotective Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 79. China Neuroprotective Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 81. China Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 82. China Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 85. China Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 86. China Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Neuroprotective Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 89. APAC Neuroprotective Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 91. APAC Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 92. APAC Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 95. APAC Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 96. APAC Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Neuroprotective Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Neuroprotective Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Neuroprotective Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Neuroprotective Drugs Sales Quantity by Region (2018-2024) & (MT)
Table 102. APAC Neuroprotective Drugs Sales Quantity by Region (2024-2034) & (MT)
Table 103. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 104. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 106. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 107. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 110. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 111. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Neuroprotective Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 117. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 118. Genervon Company Information
Table 119. Genervon Description and Overview
Table 120. Genervon Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 121. Genervon Neuroprotective Drugs Product and Services
Table 122. Genervon Neuroprotective Drugs SWOT Analysis
Table 123. Genervon Recent Developments
Table 124. NeuroVive Pharmaceutical Company Information
Table 125. NeuroVive Pharmaceutical Description and Overview
Table 126. NeuroVive Pharmaceutical Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 127. NeuroVive Pharmaceutical Neuroprotective Drugs Product and Services
Table 128. NeuroVive Pharmaceutical Neuroprotective Drugs SWOT Analysis
Table 129. NeuroVive Pharmaceutical Recent Developments
Table 130. Ceregene Company Information
Table 131. Ceregene Description and Overview
Table 132. Ceregene Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 133. Ceregene Neuroprotective Drugs Product and Services
Table 134. Ceregene Neuroprotective Drugs SWOT Analysis
Table 135. Ceregene Recent Developments
Table 136. BHR Pharma Company Information
Table 137. BHR Pharma Description and Overview
Table 138. BHR Pharma Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 139. BHR Pharma Neuroprotective Drugs Product and Services
Table 140. BHR Pharma Neuroprotective Drugs SWOT Analysis
Table 141. BHR Pharma Recent Developments
Table 142. Neuren Pharmaceuticals Company Information
Table 143. Neuren Pharmaceuticals Description and Overview
Table 144. Neuren Pharmaceuticals Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 145. Neuren Pharmaceuticals Neuroprotective Drugs Product and Services
Table 146. Neuren Pharmaceuticals Neuroprotective Drugs SWOT Analysis
Table 147. Neuren Pharmaceuticals Recent Developments
Table 148. Allon therapeutics Company Information
Table 149. Allon therapeutics Description and Overview
Table 150. Allon therapeutics Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 151. Allon therapeutics Neuroprotective Drugs Product and Services
Table 152. Allon therapeutics Neuroprotective Drugs SWOT Analysis
Table 153. Allon therapeutics Recent Developments
Table 154. Bionure Company Information
Table 155. Bionure Description and Overview
Table 156. Bionure Neuroprotective Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 157. Bionure Neuroprotective Drugs Product and Services
Table 158. Bionure Neuroprotective Drugs SWOT Analysis
Table 159. Bionure Recent Developments
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Neuroprotective Drugs Distributors List
Table 163. Neuroprotective Drugs Customers List
Table 164. Neuroprotective Drugs Market Trends
Table 165. Neuroprotective Drugs Market Drivers
Table 166. Neuroprotective Drugs Market Challenges
Table 167. Neuroprotective Drugs Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroprotective Drugs Product Picture
Figure 2. Global Neuroprotective Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Neuroprotective Drugs Market Share by Type in 2022 & 2034
Figure 4. Cholinesterase inhibitors Product Picture
Figure 5. Anti-inflammatory Product Picture
Figure 6. Others Product Picture
Figure 7. Global Neuroprotective Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Neuroprotective Drugs Market Share by Application in 2022 & 2034
Figure 9. Alzheimer's disease
Figure 10. Parkinson's disease
Figure 11. Others
Figure 12. Neuroprotective Drugs Report Years Considered
Figure 13. Global Neuroprotective Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Neuroprotective Drugs Revenue 2018-2034 (US$ Million)
Figure 15. Global Neuroprotective Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Neuroprotective Drugs Sales Quantity 2018-2034 (MT)
Figure 17. Global Neuroprotective Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Neuroprotective Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Neuroprotective Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 20. North America Neuroprotective Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Neuroprotective Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 22. Europe Neuroprotective Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Neuroprotective Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 24. China Neuroprotective Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Neuroprotective Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 26. APAC Neuroprotective Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 28. Middle East, Africa and Latin America Neuroprotective Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Neuroprotective Drugs Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Neuroprotective Drugs Revenue in 2022
Figure 31. Neuroprotective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 34. Global Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 36. North America Neuroprotective Drugs Revenue Market Share by Company in 2022
Figure 37. North America Neuroprotective Drugs Sales Quantity Market Share by Company in 2022
Figure 38. North America Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 40. North America Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 42. North America Neuroprotective Drugs Revenue Share by Country (2018-2034)
Figure 43. North America Neuroprotective Drugs Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Neuroprotective Drugs Sales Quantity Market Share by Company in 2022
Figure 47. Europe Neuroprotective Drugs Revenue Market Share by Company in 2022
Figure 48. Europe Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 50. Europe Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 52. Europe Neuroprotective Drugs Revenue Share by Country (2018-2034)
Figure 53. Europe Neuroprotective Drugs Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 55. France Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. China Neuroprotective Drugs Sales Quantity Market Share by Company in 2022
Figure 60. China Neuroprotective Drugs Revenue Market Share by Company in 2022
Figure 61. China Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 63. China Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 65. APAC Neuroprotective Drugs Sales Quantity Market Share by Company in 2022
Figure 66. APAC Neuroprotective Drugs Revenue Market Share by Company in 2022
Figure 67. APAC Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 69. APAC Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 71. APAC Neuroprotective Drugs Revenue Share by Region (2018-2034)
Figure 72. APAC Neuroprotective Drugs Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. India Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Neuroprotective Drugs Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Neuroprotective Drugs Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Neuroprotective Drugs Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Neuroprotective Drugs Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Neuroprotective Drugs Revenue Share by Country (2018-2034)
Figure 86. Brazil Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Neuroprotective Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. Neuroprotective Drugs Value Chain
Figure 92. Neuroprotective Drugs Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed